ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The major finding of this meta-analysis of 14 RCTs including 4659 CML patients was that second-generation BCR-ABL TKIs did not significantly improve short- or long-term overall survival compared with imatinib.